ABO-incompatible kidney transplantation and rituximab

Transplant Proc. 2005 Oct;37(8):3286-7. doi: 10.1016/j.transproceed.2005.09.002.

Abstract

We have designed a protocol for ABO-incompatible kidney transplantations based on antigen-specific immunoadsorption rather than plasmapheresis to remove anti-A or anti-B antibodies and with a Prograf/Cellcept/prednisolone protocol using rituximab rather than splenectomy to prevent rebound antibodies. Twelve patients have successfully received transplants with this protocol. The ABO-antibodies were readily removed by the antigen-specific immunoadsorption and maintained at a low-level posttransplantation. There were no side effects. All patients have normal renal transplant function with a follow-up of 1 to 34 months.

MeSH terms

  • ABO Blood-Group System / immunology*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD / blood
  • Antigens, CD20 / blood
  • Blood Group Incompatibility*
  • Humans
  • Immunologic Factors / therapeutic use
  • Kidney Transplantation / immunology*
  • Plasmapheresis
  • Rituximab
  • Treatment Outcome

Substances

  • ABO Blood-Group System
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD
  • Antigens, CD20
  • Immunologic Factors
  • Rituximab